Oncology and metabolic disease research by Biomea Fusion
Biomea Fusion launches Phase II trial for icovamenib in type 1 diabetes
Biomea Fusion has initiated a Phase II clinical trial, COVALENT-112, to evaluate the experimental therapy icovamenib in individuals with type 1 diabetes. Despite medical advances, many patients ...
Biomea Fusion outlines key stages involved in clinical trials for new medicines
Biomea Fusion presents a new Dr. Biomea episode focused on the clinical trial process, aiming to clarify the steps involved in bringing new medicines to market. The company addresses common ...
Biomea Fusion presents Phase II data on icovamenib in type 1 diabetes at ADA meeting
Biomea Fusion has presented new data from the Phase II COVALENT-112 study at the 86th Scientific Sessions of the American Diabetes Association, focusing on icovamenib in people with type 1 ...
COVALENT-112 Phase II data boost momentum for ico, Biomea Fusion pushes first-in-class strategy
Biomea Fusion announced new progress in its Phase II COVALENT-112 trial for type 1 diabetes, marking a significant development in the search for novel treatments. Dr. Jason Gaglia of Joslin ...
Biomea Fusion forges new industry ties at BIO International Convention
Biomea Fusion is actively expanding its network at the BIO International Convention this week, connecting with industry colleagues, collaborators, and innovators from around the global ...
Team Fusion pinpoints this year leading trends at ADA2026 event
Biomea Fusion spotlighted three major themes that shaped this year's American Diabetes Association (ADA) gathering as ADA2026 came to a close. The company reflected on the dynamic conversations, ...
Biomea Fusion unveils new icovamenib data showing durable insulin secretion gains in T1D and T2D
Biomea Fusion plans to present new data on its investigational therapy icovamenib at ADA2026. The findings indicate durable improvements in insulin secretion, C-peptide levels, and glycemic ...
Icovamenib GLP-1 therapy combination evaluated in Biomea Fusion academic study
Biomea Fusion has formed a research collaboration with the University of Leicester and the Leicester Diabetes Centre to assess the combination of icovamenib with semaglutide in the OPAL adaptive ...
Biomea Fusion icovamenib abstracts chosen for late-breaking poster presentations at diabetes conference
Biomea Fusion announced that three abstracts on its investigational therapy icovamenib have been selected for late-breaking poster presentations at the 86th Scientific Sessions of the American ...
Biomea Fusion advances COVALENT-211 and COVALENT-212 research in type 2 diabetes
Biomea Fusion conducted site visits last week at clinical study locations supporting its Phase II COVALENT-211 and COVALENT-212 trials evaluating icovamenib for type 2 diabetes. The company ...
Biomea Fusion completes Icovamenib chronic tox studies and posts 52-week follow-up in diabetes pipeline
Biomea Fusion has completed chronic toxicity studies for Icovamenib, strengthening non-clinical support for progressing to chronic clinical dosing in its diabetes and obesity programs. The ...
Icovamenib boosts C-peptide secretion in 52-week diabetes trial
Biomea Fusion reported that the recently released 52-week results from its Phase II COVALENT-112 trial evaluating icovamenib in type 2 diabetes revealed increased C-peptide secretion. Dr. G. ...
Biomea Fusion to present new icovamenib data at American Diabetes Association event
Biomea Fusion announced that three abstracts have been accepted for poster presentation at the American Diabetes Association 86th Scientific Sessions scheduled for June 5–8 in New Orleans. ...
Icovamenib explored for durable glycemic control in challenging diabetes cases
Biomea Fusion is intensifying efforts to address the unmet needs of diabetes patients who are insulin deficient and unresponsive to GLP 1 therapies by advancing the development of icovamenib, a ...
Biomea Fusion reports 52 percent C peptide AUC gain in Phase 2 diabetes trial at week 12
Biomea Fusion has announced positive 52 week results from its Phase 2 COVALENT 112 trial, which is evaluating icovamenib in patients with type 1 diabetes. The company reported a 52 percent ...
COVALENT-212 study enrolls participants for icovamenib diabetes research, Biomea Fusion initiates
Biomea Fusion announced that it is now enrolling adult participants for the COVALENT-212 clinical trial, which will evaluate the investigational drug icovamenib in individuals with type 2 ...
Biomea Fusion warns diabetes remains poorly controlled despite standard therapies
Many diabetes patients continue to struggle with inadequate blood sugar control, even when following standard-of-care therapies. This persistent challenge, as noted by Biomea Fusion, underscores ...
Icovamenib development timeline includes Phase II updates and 52-week data in 2026
Biomea Fusion has detailed its expected milestones for the Icovamenib drug programs in 2026. The company is planning to deliver 52-week follow-up data from its COVALENT-112 study in the second ...
Biomea Fusion reports 24 percent jump in insulin secretion in Phase 2 Icovamenib study
Biomea Fusion announced results from its Phase 2 COVALENT-111 study, showing Icovamenib led to significant improvements in patients with insulin-deficient type 2 diabetes. The therapy yielded ...
Biomea Fusion prioritizes key data delivery for clinical programs
Biomea Fusion announced a renewed focus on achieving significant clinical milestones and delivering pivotal data in its ongoing research programs. Following a year dedicated to execution, Biomea ...
Biomea Fusion targets new partnerships and investor interest at BIOEurope2026
Biomea Fusion announced its participation in the upcoming BIOEurope2026 conference, aiming to connect with both partners and investors. The company is seeking to advance its metabolic disease ...
